Image_7_NLRP6 controls pulmonary inflammation from cigarette smoke in a gut microbiota-dependent manner.tif by Mégane Nascimento (5445878)

Image_1_NLRP6 controls pulmonary inflammation from cigarette smoke in a gut microbiota-dependent manner.tif by Mégane Nascimento (5445878)

Metformin does not further increase the median lifespan of DR-constitutive mutant eat-2, and metformin treatment triggers several DR phenotypes in wild-type <i>C. elegans</i> witho... by Brian Onken (86790)

“…<p><b>A.</b> Survival curves of <i>eat-2(ad1116)</i> mutants raised on 0 mM, 1 mM, 10 mM, and 50 mM metformin plates at 20°C. …”

Changes in mRNA levels of microglial ion channels, transporters, and exchangers in the absence of microglial NKCC1 and after LPS treatment. by Krisztina Tóth (12009827)

“…(<b>C</b>) <i>Slc9a1</i>, <i>Slc8a1</i>, <i>Slc12a6</i>, <i>Clic1</i>, <i>Clcn3</i>, <i>Kcnk13</i>, <i>Kcnk6</i>, <i>Kcnj2</i>, <i>Sgk1</i>, <i>P2RY12</i> gene did not show altered expression between WT and NKCC1 KO microglia after intracisternal LPS treatment. …”

Amount and type of maternal dietary fat induced altered Pe-induced vasoconstriction in the offspring. by Christopher J. Kelsall (173702)

“…<p>Values are mean ± SD (n = 6/group) concentration which produced 50% maximum response (EC₅₀) such that increasing values on the y-axis correspond to decreasing vasoconstriction. …”

DataSheet_1_Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.pdf by Daniela Rivera-Pérez (10700565)

Variation of average codeword length (ACL) by number of edges. by Dario Elias (8882177)

“…A positive variation indicates a decrease in the ACL. …”

Figure S1 - E2A Predicts Prognosis of Colorectal Cancer Patients and Regulates Cancer Cell Growth by Targeting miR-320a by Ao Huang (508797)

“…Right: Change of E2A expression in SW480 cells after transfection of shE2A, E12 or E47: shE2A reduced the expression of E2A in SW480, while E12 and E47 increased E2A expression in SW480/shE2A cells, relative to the controls; (B) Transfection of E12 or E47 inhibited SW480/WT cell growth; (C) E2A regulates cell growth in NCM460 cells; (D) Transfection of E12 or E47 increased G₀/G₁ phase of SW480/WT cells and decreased the S phase; (E) E2A regulates cell cycle progression in NCM460 cells; (F) Transfection of E12 or E47 upregulated the expression of miR-320a, compared to negative control. …”

Circular Dichroism analysis, PPIase activity and nickel regulation of <i>H</i>. <i>pylori</i> WT and mutant SlyD proteins. by Milica Denic (9987685)

Optimal hydrated lime concentration in asphalt binder to improve photo degradation resistance by André Gustavo Banja (5110844)

Scutellarin’s Cardiovascular Endothelium Protective Mechanism: Important Role of PKG-I<i>α</i> by Lin Li (28817)

“…The activation of PKG–1α was then studied using targeted proteomic analysis (MRM-MS) checking the phosphorylation state of the autophosphorylation domain (aa42-94). Significant decrease in phosphorylation of PKG-Iα at Ser50, Ser72, Ser89 was induced by HR injury while SCU treatment significantly increased the phosphorylation of PKG-Iα, not only at Ser50, Ser72 and Ser89, but also at Ser44 and Thr58 (two novel phosphorylation domains). …”

Histone deacetylase (HDAC) inhibitor assessment. by Ilona Tkachyova (343715)

“…ITF 2357, an HDAC inhibitor which is structurally and functionally similar to SAHA, produced a dose-response curve with IC₅₀ of 0.2 μM. …”

Plk1 inhibition suppresses the clonogenic potential of SUM149 and SUM159. by Antonio Giordano (55096)

“…(B) EC₅₀ was defined as 50% colony inhibition. Single agents EC₅₀ were reported for each TNBC cell line and drug. …”

Regulation of MCF-7 mammosphere formation by breast cancer promoters and metformin. by Ji-Won Jung (194917)

“…On the other hand, metformin treatment decreased MCF-7 proliferation (mean ± SD, n = 3). *, <i>P</i><0.05; **, <i>P</i><0.01; ***, <i>P</i><0.001. …”

Image2_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.jpeg by Cristina López (2841392)

“…</p>Results<p>In patients with CSU under treatment with omalizumab, there was a significant decrease in the percentage of naïve and an increase in the percentage of central memory CD4 T cells as well as a decrease in the percentage of naïve and increase in the percentage of effector CD8 T-cell subsets. …”

Image1_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.jpeg by Cristina López (2841392)

“…</p>Results<p>In patients with CSU under treatment with omalizumab, there was a significant decrease in the percentage of naïve and an increase in the percentage of central memory CD4 T cells as well as a decrease in the percentage of naïve and increase in the percentage of effector CD8 T-cell subsets. …”

Table4_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.docx by Cristina López (2841392)

“…</p>Results<p>In patients with CSU under treatment with omalizumab, there was a significant decrease in the percentage of naïve and an increase in the percentage of central memory CD4 T cells as well as a decrease in the percentage of naïve and increase in the percentage of effector CD8 T-cell subsets. …”

Image3_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.pdf by Cristina López (2841392)

“…</p>Results<p>In patients with CSU under treatment with omalizumab, there was a significant decrease in the percentage of naïve and an increase in the percentage of central memory CD4 T cells as well as a decrease in the percentage of naïve and increase in the percentage of effector CD8 T-cell subsets. …”

Table3_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.docx by Cristina López (2841392)

“…</p>Results<p>In patients with CSU under treatment with omalizumab, there was a significant decrease in the percentage of naïve and an increase in the percentage of central memory CD4 T cells as well as a decrease in the percentage of naïve and increase in the percentage of effector CD8 T-cell subsets. …”

Image4_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.pdf by Cristina López (2841392)

“…</p>Results<p>In patients with CSU under treatment with omalizumab, there was a significant decrease in the percentage of naïve and an increase in the percentage of central memory CD4 T cells as well as a decrease in the percentage of naïve and increase in the percentage of effector CD8 T-cell subsets. …”